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overexpression) compared to BS153 (EGFR overexpres-
sion/EGFRvIII+). Treatment of U87MG and LN229EGFR 
cells with EGF significantly reduced cellular fluorescence, 
by promoting HO-1 transcription and expression in a con-
centration-dependent manner. This effect could be reversed 
by EGFR-specific siRNA treatment, which reduced protein 
expression of about 80% in U87MG. Remarkably, inhibi-
tion of HO-1 activity by SnPP or reduction of HO-1 pro-
tein levels by siHO-1 treatment restored fluorescence in all 
cell lines, independently of EGFR quantitative and quali-
tative expression. Gefitinib treatment was able to restore 
fluorescence after EGF stimulation in U87MG cells but 
not in BS153 cells, overexpressing EGFR/EGFRvIII. In 
GBM cell lines, 5-ALA induced fluorescence is variable 
and influenced by EGF-induced downstream activation of 
HO-1. HO-1 protein expression was identified as a negative 
regulator of 5-ALA induced fluorescence in GBM cells. 
We further propose that co-expression of EGFRvIII but not 
quantitative EGFR expression influence HO-1 activity and 
therefore cellular fluorescence.
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Introduction
High-grade gliomas and especially glioblastoma (GBM) 
is the most common and progressive tumor of the central 
nervous system. Despite current multimodality treatments 
including maximal surgical resection, followed by a com-
bination of radiotherapy and chemotherapy, the median 
survival is typically limited to 14 months after diagnosis 
[1, 2]. The extent of resection in patients with high-grade 
Abstract The extent of 5-aminolevulinic acid (5-ALA) 
guided tumor resection has a determining impact in high-
grade glioma and glioblastoma surgery. Yet the intensity 
of the 5-ALA induced fluorescence may vary within the 
tumor. We aimed to correlate 5-ALA induced fluorescence 
with the expression of epithelial growth factor receptor 
(EGFR) and its constitutively active version EGFRvIII 
in different glioblastoma (GBM) cell lines. To elucidate 
the role of EGFR in the metabolism of 5-ALA in GBM 
cell lines with variable EGFR expression status, we ana-
lyzed the activation of EGFR by its primary ligand EGF, 
and its downstream effect on Heme oxygenase-1 (HO-1), 
a key enzyme regulating the metabolism of Protoporphy-
rin IX (PpIX), the fluorescent metabolite of 5-ALA. Effects 
of direct pharmacological inhibition by Tin(IV)-Protopor-
phyrin (SnPP) or gene knockdown by small interfering 
RNA (siRNA) on HO-1 enzyme were analyzed in respect 
to 5-ALA induced fluorescence. Furthermore, inhibition 
of EGFR by Gefitinib was tested. A significant difference 
in 5-ALA induced fluorescence was obtained in U87MG 
(low EGFR expression) and LN229EGFR cells (EGFR 
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glioma and GBM can primarily impact overall survival, but 
it has to be carefully balanced with preserving the func-
tional and neurological status of the patient in eloquent 
areas [3]. Over the last several years, 5-aminolevulinic acid 
(5-ALA) has been established as an intra-operative tool to 
augment the extent of resection in high-grade glioma and 
GBM surgery [4]. Clinically, the exogenous, oral adminis-
tration of 5-ALA is usually performed 4h prior to surgery. 
5-ALA is resorbed through the upper intestine into the 
blood, where it diffuses through the blood–brain barrier, 
which has been typically disrupted by infiltrative tumor 
cells [5–9]. During fluorescence assisted tumor resection 
a variance of the fluorescence intensity within GBM can 
be observed, especially at the infiltrating zone [4, 8, 10]. 
5-ALA induced fluorescence may vary upon many fac-
tors such as cell density, proliferation index, mitochondrial 
mass and index and furthermore exogenous factors such as 
application or fading during surgery [5–8]. Schwake et al. 
have shown that in GBM cell lines continuous exposition 
of 5-ALA continuously increased 5-ALA induced fluores-
cence up to 24 h [11].
5-ALA is an indirect fluorophore and an early precur-
sor molecule in the heme biosynthetic pathway, endoge-
nously synthesized from the cells starting from glycine and 
succinyl-CoA.
Upon uptake into the cell, 5-ALA is metabolized by sev-
eral enzymatic steps first within the cytoplasm and then 
into in the mitochondrial membrane to Protoporphyrin IX 
(PpIX), a compound capable of fluorescence when excited 
by appropriately filtered light. PpIX is further converted 
into heme, a non-fluorescent compound, by the enzyme 
Ferro-chelatase (FECH) [9]. Several studies have demon-
strated that in general, tumor and highly proliferating tis-
sues tend to exhibit higher level of PpIX than normal cells 
after 5-ALA incubation [12]. Indeed, multiple primary and 
metastatic CNS neoplasms notably take up preferentially 
exogenous 5-ALA and store it as PpIX, thus facilitating the 
neurosurgeon to accomplish an easier and more accurate 
tumor resection [13].
Although the PpIX synthesis does not solely result from 
the Porphobilinogendeaminase (PBDG) production and the 
FECH conversion, the balance does play an important role 
in the PpIX accumulation [9]. Other factors contributing 
to PpIX accumulation, specific to GBM, are reported from 
in vitro studies and include the NADPH imbalance and its 
effect on HO-1 [14]. Furthermore, Gandini et al. reported 
the higher frequency of HO-1 protein expression in human 
gliomas compared to non-malignant brain samples, justi-
fied by the HO-1 modulation of glioma cell proliferation. 
The effect is discussed to be in relation to the downstream 
effects of the products the PpIX metabolism [15].
The epithelial growth factor receptor (EGFR, also called 
ErbB-1), a member of the ErbB receptor family, is a 170-kDa 
glycosylated cell-surface receptor with tyrosine kinase activ-
ity [16]. EGFR has been thoroughly associated with several 
distinct steps in tumorigenesis, cell migration and angiogen-
esis. Upon binding of its natural ligand, the epidermal growth 
factor (EGFXX), the EGFR undergoes a conformational 
change which promotes dimerization, activation of the intra-
cellular tyrosine kinase and autophosphorylation. This results 
in the activation of signal transduction molecules, includ-
ing PI3 kinase, Akt and nuclear factor (NF-kβ) proteins, 
ultimately leading to tumor proliferation and progression, 
reduced apoptotic capacity, angiogenesis and the metastatic 
phenotype [17].
EGFR can exert oncogenic effects by different mecha-
nisms, such as autocrine growth factor loops, amplification of 
the EGFR gene and deletions/mutations that render the recep-
tor constitutively active [18, 19]. The most common mutation 
of the EGFR gene is a deletion of exons 2–7, producing an 
extracellularly truncated, constitutively-active EGFR, named 
EGFR variant III (EGFRvIII). Approximately 40% of GBM 
show EGFR gene amplification resulting in protein overex-
pression; among these ~50% express EGFRvIII [20, 21]. 
Remarkably, EGFRvIII expression is associated with con-
comitant (over) expression of the wild-type EGFR gene [22]. 
Hence, GBM could be subdivided into EGFR wild-type, 
EGFR overexpressing and EGFR/EGFRvIII co-expressing 
tumors.
All this considered, EGFR currently represents an attrac-
tive and promising target in high grade and GBM therapy. 
Yet intratumoral heterogeneity of EGFR/EGFRvIII expres-
sion in GBM may ultimately limit and challenge diagnostic 
and therapeutic utility in the clinical setting [23].
Expression of the HO-1 gene (HMOX.1) is primarily reg-
ulated at the transcriptional level by activating transcription 
factors such as NF-kβ, AP-2, and the heat shock-responsive 
element (HSE) [24–26]. Several reports showed that EGF-
induced NF-kB activation occurs through multiple EGFR-
dependent signaling molecules, including PI3K, protein 
kinase C (PKC), and IKK signaling pathways [27].
We were particularly interested to understand how EGF 
regulates the induction of HO-1 protein expression in cancer 
cells. We hypothesized that in GBM cells, EGFR activation 
by its main ligand EGF may act as a negative regulator of 
5-ALA-induced PpIX fluorescence, through induction of the 
enzyme HO-1 (Fig. 1).
Here, we use GBM cell lines with different EGFR expres-
sion levels to elucidate the molecular role of EGFR activation 
in 5-ALA-induced fluorescence.




The human GBM cell line U87MG (Sigma-Aldrich, 
USA) was cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, 61965-026,  gibco® Life technolo-
gies™, UK) GlutaMAX cell culture medium supple-
mented with 10% fetal bovine serum (FBS, 10270-106, 
 gibco® Life technologies™, UK), 1% non-essential 
amino acids (NEAA, 11140-035,  gibco® Life technolo-
gies™, UK), 1 mM sodium pyruvate and penicillin–strep-
tomycin (100–100 μg/ml) (S8636, Sigma-Aldrich, USA). 
The human GBM cell line BS153 was kindly provided 
by the laboratories of Prof. Monika Hegi (Laboratory of 
Brain Tumor Biology and Genetics—University Hospital 
Lausanne, Switzerland) and was maintained in DMEM 
GlutaMAX, 10% FBS and 1% penicillin–streptomycin. 
BS153 is a GBM cell line immortalized first by Jones 
et al., which has retained amplification of the EGFR gene 
and expression of the EGFRvIII+ [28] LN229 cells over-
expressing the EGFR gene (LN229EGFR) were gener-
ously provided by Proffesor Michael Weller (Department 
of Neurology, University Hospital Zurich, Switzerland) 
and maintained in DMEM GlutaMAX, 10% FBS and 
1% penicillin–streptomycin, enriched with Hygromycin 
GOLD 60ug/ml.
As a control cell line, we used the immortalized astro-
cyte cell line IMA2.1, kindly provided by Dr. Stefan Schil-
dknecht (University of Konstanz, Germany) [29], cultured 
in DMEM GlutaMAX, 10% FBS and penicillin–streptomy-
cin. All cells were kept at 37 °C, 5%  CO2 atmosphere, in 
static conditions.
Drug treatment
5-ALA was obtained directly from the Hospital Pharmacy 
(Fagron DAC 2011, Germany) and freshly dissolved in dis-
tilled water. Cells were incubated for 18  h. EGF (E9644, 
Sigma-Aldrich, USA) was reconstituted in RNAase- and 
DNAase-free water and added to the cells for 18  h. The 
continuous exposition of cell lines to 5-ALA in compari-
son to short exposition times, has been previously reported 
to prevent fading of 5-ALA induced fluorescence for up 
to 24  h [11]. SnPP (CAS 14325-05-4, Santa Cruz Bio-
tech, USA) was dissolved in DMSO and added to the cells 
1 h prior to 5-ALA treatment. Gefitinib was ordered from 
Sigma–Aldrich (St. Louis, MO, USA), dissolved in DMSO 
to a final concentration of 10–20 µM and added to the cell 
culture 2 h prior to EGF treatment.
Fig. 1  Representation of the 5-ALA metabolism as a function of the 
regulation of EGFR in GBM cells. EGF/EGFR signaling promotes 
HO-1 expression and activity in GBM cells through activation of 
the PI3K/AKT/NF-κB cascade, leading to cell proliferation. 5-ALA 
5-aminolevulinic acid, EGF epidermal growth factor, EGFR epider-
mal growth factor receptor, HO-1 heme oxygenase-1, PI3K phospha-
tydil-inositol-3-kinase, NF-kB nuclear factor k-beta
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Antibodies
The following antibodies were used:
Rabbit monoclonal anti-EGFR (ab52894, Abcam, 
Cambridge, UK); mouse monoclonal anti-EGFR (sc-120, 
Santa Cruz Biotechnology, USA); mouse monoclonal 
anti-EGFRvIII (L8A4, Absolute Antibodies, UK); rab-
bit polyclonal anti-EGFR (ab5652, Abcam, UK); mouse 
monoclonal anti-HO-1 (ab13248, Abcam, UK); mouse 
monoclonal anti-β-actin (AC-15, Sigma-Aldrich, USA); 
 IRDye® 800CW goat anti-mouse IgG (827-08364, LI-
COR Biotechnology, Germany);  IRDye® 680RD goat 
anti-rabbit IgG (926-68071, LI-COR Biotechnology, 
Germany).
siRNA transfection
Transfection of U87MG cells was performed 24 h before 
plating. siRNAs were used at a concentration of 25  nM 
(siEGFR) and 10  nM (siHO-1) with 1.7 μl/ml Lipo-
fectamin RNAiMAX (18324-012, Invitrogen™ Thermo 
Fisher Scientific, USA). The following siRNA sequences 
were used: siCtrl: 5′-CGT ACG CGG AAT ACT TCG 
AdTdT-3′; siEGFR and siHO-1: Dharmacon™ ON-TAR-
GET plus SMARTpool against human EGFR (L-003114-
00, GE Healthcare Europe GmbH, Switzerland) and 
human HMOX1 (L-006372-00, GE Healthcare Europe 
GmbH, Switzerland).
Confocal microscopy
Cells were plated into Ibidi μ-slides VI0.4 (80606, Ibidi, 
Munich). The next day medium was substituted with 
FBS-free medium for at least additional 24  h prior to 
treatment with 1–10  ng/ml EGF. Following incubation 
with EGF, 1 mM 5-ALAwas added to the cell culture. At 
the desired time point, cells were washed twice with PBS 
(10010-015,  Gibco® Life technologies™, UK), fixed with 
4% paraformaldehyde/PBS for 10 min, washed with PBS 
(4 × 5  min) and stored at 4 °C until staining. Cells were 
permeabilized for 5 min with 0.5% ice cold Triton-X-100/
PBS, blocked for at least 20 min with 1% BSA, followed 
by 1  h incubation with the selected primary antibody, 
diluted in 1% BSA/PBS. After washing with 1% BSA/
PBS (3 × 10  min), cells were incubated with the appro-
priate secondary antibody diluted 1:1000 (Alexa  Fluor® 
488 and/or Alexa  Fluor® 594; Invitrogen), washed with 
1% BSA/PBS (2 × 10 min) followed by PBS (1 × 10 min) 
and incubated with 1  μg/ml DAPI/methanol for 3  min 
and washed with PBS (3 × 10 min). Slides were examined 
with a Nikon ECLIPSE Ti-E confocal microscope and a 
Nikon C2 camera. Merged z-stacks (z = 0.49  µm) were 
analyzed with NIS-Elements AR software (Nikon). At 
least 50 cells/condition were analyzed.
Flow cytometry analysis
To quantify the extent of PpIX biosynthesis induced by 
5-ALA, we measured cellular fluorescence intensity in liv-
ing cells using a flow cytometer (FC, AT01008, Navios™, 
Beckman Coulter), as previously described [30]. Cells were 
plated into 10 cm dishes and transfected with either mock 
or siHO-1 RNA. The next day, medium was substituted 
with FBS-free medium for at least 24 h prior to treatment 
with EGF. Following 18 h of EGF treatment, 5-ALA was 
added to the cell culture and at the desired time points, cells 
were harvested in the dark for FACS analysis. The auto-flu-
orescence intensity of PpIX, following 5-ALA administra-
tion, was measured with excitation at 488 nm and an emis-
sion peak of PpIX corresponding to 620 nm (605–635 nm) 
[31]. Auto-fluorescence signal of cells (fluorescence sig-
nal obtained in the absence of 5-ALA treatment) was also 
quantified and plotted as “untreated” in all the graphs 
shown in the “Results” section. The intensity of the fluo-
rescence signal in the cell lines was quantified by comput-
erized calculation (Kaluza Version 1.2, Beckman Coulter) 
by calculating the geometric means of the data distributions 
 (Gmean) from the signal plot. FACS parameters were always 
kept equal among all measurements.
To quantify the expression of EGFR and EGFRvIII in 
U87MG and in BS153, receptor density was measured by 
flow cytometry. In brief, cells were plated into 10 cm dishes 
and at the desired time points harvested and washed with 
ice cold PBS. Cells were then re-suspended and diluted 
to approximately 5 × 106 cells/ml. Primary antibody in 3% 
BSA/PBS was added and cells were incubated for 1  h at 
4 °C in the dark. After incubation, cells were centrifuged 
at 18,406×g for 5 min and fixed for 15 min with 100 µl of 
4% paraformaldehyde (pH 7.4). Following fixation, cells 
were washed for three times by centrifugation (18,406×g 
for 5 min) and then incubated with the secondary antibody 
Alexa  Fluor® 488 (Invitrogen). After incubation cells were 
washed twice and then resuspended in FACS buffer (1% 
bovine serum albumin, 0.1 M EDTA in PBS) before analy-
sis by FACS.
Western blotting
At the indicated time points, cells were collected in PBS 
and centrifuged. The cell pellet was suspended in RIPA 
buffer and rested in ice for 30  min, followed by cen-
trifugation at 21,130×g for 15  min. Cell extracts were 
collected, frozen in dry ice and stored at −80 °C until 
analysis. Equal protein amounts (30  µg) were run on a 
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10% polyacrylamide gel and blotted onto polyvinylidene 
difluoride (PVDF, 162-0177, Bio-Rad, USA) membranes 
by semi-dry electroblotting. Membranes were stained 
with Ponceau S to verify equal protein loading per lane. 
Membranes were blocked for 1  h with blocking buffer 
(Blocking solution (927-50000, LI-COR, Germany), 
TBS (200 mM Tris/Cl, 1.5 M NaCl, HCl, Milli-Q water), 
Milli-Q water). All antibodies were diluted in antibody 
dilution buffer (Blocking solution, TBS 0.1% Tween 20, 
Milli-Q water). Primary antibody detection was achieved 
through the use of the following secondary antibodies: 
 IRDye® 800CW goat anti-mouse IgG (827–08364, LI-
COR Biotechnology, Germany);  IRDye® 680RD goat 
anti-rabbit IgG (926-68071, LI-COR Biotechnology, 
Germany).
Real-time PCR. To amplify human colon cancer 
cell HO-1 mRNA, specific primers were synthesized. 
The HO-1 primers used were: 5′-TAG AAG AGG CCA 
AGA CTG CG-3′ (forward, Microsynth, Switzerland) 
and 5′-CAG AAT CTT GCA CTT TGT TGC-3′ (reverse, 
Microsynth, Switzerland). GADPH mRNA levels were 
used as an internal control. At the indicated time points, 
cells were harvested and RNA was extracted using TRI-
REAGENT (Molecular Research Center, USA) according 
to the manufacturer’s instructions. For the reverse tran-
scription reaction we used oligo-dT primers (GoScript™ 
Reverse Transcription System, A5000, Promega, Swit-
zerland). The reaction was incubated at 42 °C for 15 min, 
then samples were heated at 95 °C for 5 min, followed by 
incubation at 0–5 °C for 5  min. Real-time RT-PCR was 
performed using  SYBR® Green Supermix (172-5271, 
SsoAdvanced™ Universal, Bio-Rad, USA) according to 
the manufacturer’s instructions. Briefly, equal amounts 
of each cDNA were PCR-amplified with Tag polymerase 
in at least 35 cycles consisting of 30  s at 95 °C, 30  s at 
58 °C, and 1 min at 72 °C. At the end of the PCR, a melt-
ing curve analysis was performed by gradually increasing 
the temperature to 95 °C. Data acquisition was performed 
during the elongation step. After PCR completion, the 
SYBR Green fluorescent signal was transformed into 
a relative number of copies of target molecules. Differ-
ences in cDNA amounts were normalized as a function of 
the expression of the housekeeping gene GADPH.
Statistical analysis
Data were presented as the mean ± standard deviation 
(SD) of at least three independent experiments. Statistical 
analysis was performed using Prism 5 GraphPad (version 
7 for Windows, USA, http://www.graphpad.com). A Sha-
piro–Wilk test was used to determine the data normality. 
The results indicated that parametric tests should be used 
for the comparisons. The results were then tested for sig-
nificance using the two-sided unpaired Student’s t test. 
Results were considered statistically significant when 
p < 0.0.5 (*).
Results
5-ALA-derived fluorescence varies among GBM cell 
lines with different EGFR expression
Some clinical reports have shown that during 5-ALA 
induced fluorescence for guided tumor resection, some 
GBMs may exhibit areas, especially at the infiltrating zone, 
with weak to no fluorescence perceptible to the naked 
eye [4, 10]. We screened glial and GBM cells for their 
PpIX fluorescence intensity after treatment with 5-ALA 
(Fig.  2a). Positive fluorescence was found for both GBM 
cell lines U87MG and BS153, with significantly more 
intense PpIX fluorescence in U87MG when compared to 
BS153 cells. In contrast, the non-cancerous glial cell line 
IMA2.1 did not exhibit PpIX fluorescence. Analysis by 
immunofluorescence of U87MG cells confirmed the co-
localization of PpIX with TOMM20, a known mitochon-
drial membrane marker (Fig. S1, supplementary material). 
Moreover, analysis by flow cytometry confirmed maximal 
5-ALA induced fluorescence in U87MG cells incubated 
for 18  h with 5-ALA (Fig. S2, supplementary material). 
We then investigated which molecular characteristics could 
contribute to this difference. The U87MG cells express 
relatively low levels of EGFR and virtually do not express 
the mutant form EGFRvIII. In contrast, BS153 cells over-
express EGFR and co-express EGFRvIII, as assessed by 
immunofluorescence (Fig.  2b) and western blot (Fig.  2c). 
We further analyzed EGFR by flow cytometry, which 
showed a tenfold higher expression of EGFR in BS153 
compared to U87MG cells. Furthermore, the expression of 
EGFRvIII was unique to the BS153 cell line (Fig. 2d). In 
LN229 overexpressing EGFR (assessed by western blot) 
the 5-ALA induced fluorescence was significantly higher 
than in BS153 (Fig. S8).
EGF induces HO-1 expression in U87MG cells
We choose U87MG cells to investigate the role of the EGF 
signaling pathway in the regulation of HO-1 expression. 
Treatment with 1, 10 and 20 ng/ml EGF induced HO-1 pro-
tein expression in a concentration-dependent manner, with 
an approximate threefold increase at the highest concentra-
tions when compared to untreated cells (Fig. 3a, S3). EGFR 
stimulation by EGF has been shown to activate NF-kB, 
which promotes transcription of several genes, including 
HO-1. Therefore, we investigated whether upregulation of 
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HO-1 protein by EGF was occurring at the transcription 
level. The treatment of U87MG cells with EGF 10 ng/ml 
allowed us to determine that the induction of HO-1 mRNA 
reached its maximum at 8 h, with a 20-fold increase in tran-
scription rate (Fig. 3b) in comparison to untreated cells. To 
demonstrate the involvement of EGFR in EGF-mediated 
induction of HO-1, we treated U87MG cells with siRNA 
(25 nM) specific for the EGFR. Down-regulation of EGFR 
strongly reduced EGF-induced HO-1 expression (Fig.  3c) 
and mRNA transcription (Fig. 3d) when compared to con-
trol siRNA treated cells. Therefore, our data indicate an 
involvement of EGFR in EGF-mediated HO-1 expression 
in U87MG cells.
Selective inhibition or siRNA-mediated depletion 
of HO-1 increases 5-ALA fluorescence
To test the role of HO-1 in the metabolism of PpIX, we 
incubated U87MG cells with SnPP, a potent inhibitor of 
HO-1 enzymatic activity. As described above, the pres-
ence of 5-ALA (1  mM) promoted porphyrin biosynthesis 
and thus cellular fluorescence. Pharmacological treatment 
with SnPP further increased cellular 5-ALA fluorescence 
(Fig. 4a, S5). In order to confirm the link between PpIX flu-
orescence and HO-1 expression, we down-regulated HO-1 
protein expression in U87MG cells (Fig.  4b). Similarly 
to SnPP treatment, siRNA-mediated depletion of HO-1 
Fig. 2  5-ALA fluorescence variability among GBM cells with dif-
ferent EGFR status. Protoporphyrin IX fluorescence after treatment 
with 5-ALA (a) among different GBM cell lines with variable EGFR/
EGFRvIII expression status (b). EGFR and EGFRvIII protein levels 
as assessed by western blot (c) and flow cytometry (d, fluorescence 
relative to control conditions, i.e. no primary antibody, only with the 
secondary antibody)
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enzyme significantly increased cellular 5-ALA fluores-
cence. The effect of siRNA-depletion was somehow infe-
rior to that induced by SnPP. Nevertheless, treatment with 
SnPP in HO-1-depleted cells did not have any synergistic 
effect on fluorescence (Fig. 4a).
HO-1 inhibition, reversed reduction of EGF-induced 
fluorescence in GBM cells independently of their 
EGFR/EGFRvIII quantitative expression
We then investigated if EGFR activation and subsequent 
HO-1 induction was the cause for reduced PpIX and 
impaired cellular fluorescence in GBM cells. In order to 
remove EGF from culturing conditions, cells were cul-
tured in serum-free medium for 24  h, after which EGF 
(10 ng/ml) was added to the culture medium, 18 h prior 
to addition of 5-ALA. Consistent with the data described 
above, U87MG cells displayed lower 5-ALA fluorescence 
in the presence of EGF for 18 h when compared to EGF-
depleted conditions (Fig. 5a1, a2). This effect was likely 
to be caused by HO-1-mediated degradation of PpIX, 
because selective pharmacological inhibition of HO-1 by 
SnPP restored PpIX fluorescence in GBM cells, indepen-
dently of their quantitative expression of EGFR, as shown 
Fig. 3  EGF stimulates HO-1 expression in U87MG cells. U87MG 
cells were incubated with various concentrations of EGF (1 and 
10 ng/ml) for 18 h, followed by Western Blot to assess HO-1 levels 
(a). To determine HMOX1 gene expression, cells were treated with 
EGF (10  ng/ml), after which total RNA was extracted. A real-time 
PCR was carried out as described in ‘‘Materials and methods’’ sec-
tion to assess HMOX1 mRNA levels relative to the control, untreated 
cells (b). Cells were transiently transfected with 25 nM control (siC-
trl) or EGFR siRNA (siEGFR) for at least 24  h, then treated with 
EGF (10  ng/ml). After 18  h, cell lysates were collected and HO-1 
and EGFR protein levels assessed by immunoblotting (c). EGFR was 
downregulated by siRNA-treatment in U87MG cells, followed by 
treatment with EGF (10 ng/ml). After 4 h, total RNA was extracted to 
determine HMOX1 mRNA levels, relative to control cells transfected 
with transfection reagent alone (d). *Represents p < 0.05, compared 
to EGF treatment
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by Flow Cytometry (Fig.  5a1) and immunostaining 
(Fig. 5a2). Also at basal HO-1 expression conditions, i.e. 
in the absence of EGF, SnPP treatment increased PpIX 
fluorescence in the U87MG cells. Overall, these data 
confirm our hypothesis that EGF acts through its receptor 
to regulate 5-ALA fluorescence, and that HO-1 expres-
sion dramatically impacts 5-ALA-induced fluorescence.
HO-1 inhibition restores 5-ALA-fluorescence in BS153 
cells
Human BS153 GBM cells were used to investigate the role 
of EGFR/EGFRvIII expression in 5-ALA fluorescence. 
Analysis by flow cytometry (Fig.  5b1) and the immu-
nostaining (Fig.  5b2) showed that inhibition of HO-1 by 
SnPP completely restored PpIX fluorescence in the BS153 
cell line (Fig. 5b2). However, EGF-treatment had no signif-
icant effect on PpIX fluorescence in BS153 cells exposed 
to 5-ALA up to 5 mM in the absence or presence of SnPP 
(Fig. 5b2). We thus hypothesized that the lack of EGF effect 
and reduced PpIX fluorescence in BS153 cells was caused 
by the constitutive activation of the EGFR/EGFRvIII path-
way, consequently inducing a constitutive over-expression 
of HO-1. Indeed, HO-1 mRNA levels cells were up to five-
fold higher in BS153 when compared to U87MG cells (Fig. 
S5) and HO-1 inhibition in response to high concentration 
of SnPP (500 µM) restored the PpIX fluorescence in BS153 
independently of the presence of EGF (Fig. 5b1 and S6). To 
elucidate the role of EGFR overexpression over its consti-
tutively active form EGFRvIII, we screened LN229EGFR 
GBM cells (both overexpressing the EGFR protein, without 
expressing the constitutively active version EGFRvIII) for 
their 5-ALA-induced fluorescence. LN229 cell line shows 
high level of fluorescence as assessed by Flow Cytometry 
compared to BS153 (Fig. S7). Treatment with EGF 10 ng/
ml could reduce fluorescence, in a proportional way with 
respect to the U87MG and the effect was strongly reversed 
by treatment with SnPP.
Gefitinib Inhibition restored fluorescence in U87MG 
cells, but not in BS153 cells
Treatment with the selective Tyrosine Kinase Inhibitor 
(TKI) Gefitinib (10 µM) restored 5-ALA induced fluores-
cence of EGF stimulated U87MG cells while normalizing 
HO-1 activity to baseline. No effect of EGFR inhibition by 
Gefitinib (at 10 and 20 µM) upon 5-ALA induced fluores-
cence on BS153 cells was seen, maintaining constant high 
HO-1 activity (Fig S8).
Discussion
Even though high grade glioma and GBM are considered 
diffuse and infiltrating diseases, increasing the magnitude 
of surgical tumor resection can impact overall survival in 
studies of high-grade gliomas, including GBM. 5-ALA-
aided surgery has been established as an efficient tool to 
increase the accuracy and extent of resection of high-grade 
tumors and thus is part of the standard procedure during 
Fig. 4  Inhibition or siRNA (siHO-1)-mediated depletion of HO-1 
increases 5-ALA fluorescence in U87MG Cells. Cells were tran-
siently transfected with either control or HO-1 siRNA, followed by 
incubation for 18  h with 5-ALA (1  mM) with or without the pres-
ence of the pharmacological HO-1 inhibitor SnPP (100  µM) (a). 
HO-1 protein levels of siHO-1-treated U87MG cells, determined at 
48  h post-transfection (b). *p < 0.05 compared to untreated cells, if 
not specified otherwise
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tumor removal [9]. 5-ALA induced fluorescence may vary 
upon many factors such as cell density, proliferation index, 
mitochondrial mass and, furthermore, exogenous fac-
tors such as application or fading during surgery [10, 23]. 
Moreover, Jaber et al. have recently shown in patients har-
boring gliomas, that there is a strong correlation between 
tumor volume, contrast enhancement, age and 18F-fluoro-
ethyl tyrosine positron emission tomography uptake ratio, 
which is predictive of the fluorescence of different grade 
gliomas after 5-ALA administration [32]. Furthermore, 
during surgery, the magnitude of fluorescence may be influ-
enced by factors such as logistical changes in time of resec-
tion after 5-ALA administration, its reabsorption, and vari-
ations in its passage through the blood brain barrier. While 
both 5-ALA passive and active uptake mechanisms, and 
their consequent implication in the time rate of the induced 
fluorescence, are still under discussion [5–8], the inter-
observer variability of the 5-ALA-induced fluorescence 
remains unaddressed in the clinical setting.
It is known that PpIX, the actually fluorescent 5-ALA 
metabolite, has a complex biosynthesis and metabolism, 
with several enzymes involved. Among them, HO-1 has 
been shown to decrease the PpIX concentration [30]. Nota-
bly, HO-1 activity is regulated by various stimuli. Recently, 
EGF stimulation was shown to increase HO-1 through 
NF-kβ activation in colon cancer and in non-small cell lung 
cancer [26, 33].
Fig. 5  a EGF treatment reduces 5-ALA fluorescence in U87MG 
cells through induction of HO-1. U87MG cells were plated and after 
24  h, medium was changed to FBS-free serum for additional 24  h. 
EGF (10  ng/ml) or mock treatment was added, followed by treat-
ment with 5-ALA with or without SnPP (100  µM). Fluorescence 
was assessed by flow cytometry (a1) or by immunostaining (a2). 
*p < 0.05, compared to untreated cells, if not otherwise specified. b 
5-ALA-induced fluorescence in BS153 cells can be restored by treat-
ment with SnPP, a potent HO-1 inhibitor. BS153 cells were plated 
and, after 24  h, medium was switched to FBS-free serum for addi-
tional 24 h. EGF (10 ng/ml) or mock treatment was added, followed 
by treatment with 5-ALA with or without SnPP (100 µM). Fluores-
cence was assessed by flow cytometry (b1) or by immunostaining 
(b2). *p < 0.05 compared to untreated cells, if not otherwise specified
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In the present study, we investigated the role of EGF 
in the metabolism of 5-ALA as a possible cause of vari-
ability in tumor-associated fluorescence in GBM cells. In 
our human cell tumor cultures, EGF stimulation induced 
a significant increase in HO-1, both at mRNA and protein 
expression levels, and a significant reduction in 5-ALA flu-
orescence. The data indicate that these effects were directly 
correlated with activation of the EGFR, as siRNA mediated 
knockdown of EGFR significantly hampered EGF-depend-
ent HO-1 induction.
PpIX is not a direct substrate for HO-1 enzymatic activ-
ity. Instead, it must be converted into heme by the enzyme 
FECH before it can be further metabolized by HO-1. We 
hypothesized that the EGF-mediated increase in HO-1 
would result in accelerated heme depletion and thus a shift 
in enzymatic activity in favor of increased PpIX metabo-
lism by FECH. Supporting this notion, we show that 
pharmacological blockade of HO-1 by SnPP significantly 
increased cellular 5-ALA fluorescence. Similarly, siRNA 
mediated down-regulation of HO-1 increased cellular fluo-
rescence whilst abolishing the SnPP effect. Taken together, 
our data show that increased EGFR activity results in up-
regulation of HO-1-mediated heme clearance and, ulti-
mately reduced PpIX fluorescence.
BS153 cells overexpress EGFR as well as the consti-
tutively active EGFRvIII+. We thus assumed that even in 
the absence of any EGF stimulation, BS153 cells would 
display increased levels of HO-1 protein and reduced 
PpIX fluorescence. Indeed, even in EGF-depleted, serum-
free culturing conditions, no fluorescence was observed in 
BS153 cells. Treatment with high-dose SnPP (up to five-
fold compared to U87MG cells) was able to restore PpIX 
fluorescence in BS153 cells, clearly highlighting the role 
of HO-1 in 5-ALA-induced, or lack of, GBM tumor fluo-
rescence. Interestingly LN229EGFR cells, which do over-
express EGFR but are negative for EGFRvIII, show high 
levels of 5-ALA-induced fluorescence, comparable with 
U87MG cells. The observation that 5-ALA fluorescence is 
dependent on the activity of HO-1, which in turn is depend-
ent of the activity of EGFR, is clinically relevant as it 
underlies the clinical findings of possible low or absence of 
fluorescence to the naked eye as reported by Hauser et al. 
Thus, together our findings suggest that intra-tumoral heter-
ogeneity of EGFR/EGFRvIII expression might explain the 
intra-tumoral variability in 5-ALA induced fluorescence 
expression, resulting, as previously reported, in false nega-
tive areas of tumor infiltration [10, 23].
Interestingly Gefitinib, a selective inhibitor of EGF 
tyrosine kinase receptor, was not capable of restor-
ing PpIX fluorescence in BS153 cell cultures. Levels of 
Gefitinib sufficient to suppress EGFRwt phosphoryla-
tion (0.01–0.1  µM), have been previously shown to be 
insufficient to inhibit the same feature in cells express-
ing EGFRvIII [34], suggesting the difficulty of blocking 
the mutated and constitutively active EGFR receptor. Our 
results further support those findings, as a concentration 
of Gefitinib approximately tenfold higher than that used to 
inhibit EGFRvIII in different cell lines was not enough to 
restore the PpIX fluorescence in BS153 cells. Together, the 
data suggests that the expression level of EGFRvIII and its 
varying degree of resistance to inhibition by Gefitinib in 
the clinical setting, may justify why GBM tumor tissue can 
be present yet not visible by 5-ALA-induced fluorescence.
Taken together, our findings seem to indicate that EGFR 
plays a relevant role in cellular fluorescence upon treatment 
with 5-ALA. Notably, the presence of EGFRvIII, which is 
constitutively active even in absence of EGF, strongly ham-
pers fluorescence. Overexpression of EGFR alone seems 
not to influence the intensity of fluorescence; neverthe-
less upon treatment with EGF, fluorescence was strongly 
reduced in these cells, highlighting the role of increased 
EGF-induced HO-1 expression and turn-over of PpIX.
These findings do not disagree with the utility of fluo-
rescence assisted resection surgery; instead the data points 
to a problem strongly impacting the definition of the tumor 
border, and draws a possible justification for the cases of 
reported low or no visible 5-ALA induced fluorescence 
despite histological confirmation of the tumor presence, 
especially at the infiltrating zone. These findings highlight 
the need to evaluate clinical databanks, in order to confirm 
or negate the evidence suggested by the in  vitro results. 
However, our in vitro results support an explanation for the 
event of low, or absence of, visible 5-ALA induced fluores-
cence in histologically-confirmed GBM, which contributes 
for a new perspective of the problem and inviting to rethink 
a strategy to address these questions.
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